Traders should monitor upcoming three-year clinical data in H2 2026 and watch for potential partnership announcements, especially given the strong immune response correlation with AI predictions. This data strengthens EVAX's platform story, which may attract biotech interest despite small market cap.
Price Chart
Executive Summary
Evaxion announced new Phase 2 data for its AI-designed personalized cancer vaccine EVX-01, showing 86% of vaccine targets triggered a tumor-specific immune response—a rate higher than previously reported methods. The data, to be presented at AACR, also show durable immune responses and de novo T-cell activation, reinforcing the predictive power of its AI-Immunology™ platform.
Key Facts
- 86% of vaccine targets in EVX-01 triggered a tumor-specific immune response, a record-high rate
- Durable de novo T-cell responses observed, with 86% of responses being novel tumor-specific T cells
- Positive correlation between AI-prediction scores and immune response magnitude confirms platform accuracy
- Phase 2 trial in advanced melanoma combines EVX-01 with KEYTRUDA® (pembrolizumab), showing 75% Objective Response Rate at two years
- Three-year clinical data expected in H2 2026
Financial Impact
Potential re-rating of EVAX based on clinical validation of AI platform and vaccine efficacy; increases likelihood of partnership or licensing interest
Risk Factors
- Clinical outcomes may not improve proportionally despite strong immune response
- High market expectations could lead to sell-off if H2 2026 data disappoints
- Dilution risk given $35M market cap and likely need for future funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276460 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access